ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Diabetes gene therapy firm Kriya launches

by Ryan Cross
May 15, 2020 | APPEARED IN VOLUME 98, ISSUE 19

 

Nearly all gene therapy programs are focused on treating rare diseases caused by a single genetic mutation. Now, a new company, Kriya, has raised $80.5 million in series A funding to develop gene therapies for common diseases, including diabetes. The firm’s three lead therapies will encode insulin growth factor 1 for type 1 diabetes; a glucagon-like peptide 1 receptor agonist for type 2 diabetes and obesity; and insulin and glucokinase for both type 1 and type 2 diabetes. Kriya’s roster includes former leaders of the gene therapy firms AveXis, Roivant Sciences, Sangamo Therapeutics, and Spark Therapeutics.

X

Article:

This article has been sent to the following recipient:

Comments
Sheldon Seltzer (May 17, 2020 9:41 AM)
As a 78 year old male who has been living with diagnosed diabetes (II) over thirty years, I applaud Kriya"s attempt to explore additional gene therapy to help relieve, or hopefully, eradicate this disease. Thank you for all your efforts.

Leave A Comment

*Required to comment